Monitoring tumor burden and treatment response in metastatic breast cancer patients often relies on invasive biopsies, which can be painful, costly, and may not accurately represent the entire tumor landscape. Current methods may also lack the sensitivity to detect minimal residual disease or early signs of relapse.

mDETECT offers a DNA-methylation-based liquid biopsy technology designed to provide a comprehensive assessment of tumor burden and treatment response in metastatic cancer patients. By analyzing methylation patterns in circulating tumor DNA, the technology aims to deliver detailed, personalized data on cancer progression and relapse. This non-invasive approach enables oncologists to gain insights into the dynamics of the disease, facilitating more informed treatment decisions and improved patient management. The liquid biopsy provides a less invasive and potentially more representative snapshot of the tumor's characteristics compared to traditional tissue biopsies.

DNA-methylation analysis of circulating tumor DNA (ctDNA)

Non-invasive monitoring of tumor burden

Assessment of treatment response

Detection of minimal residual disease

Early detection of relapse

Personalized data on cancer progression

The primary target audience includes oncologists specializing in metastatic breast cancer and other metastatic cancers, as well as hospitals and cancer centers that manage patients with advanced-stage malignancies.